Response Oncology (Response Oncology) EV-to-EBIT

Response Oncology Annual Data
	Trend	Dec92	Dec93	Dec94	Dec95	Dec96	Dec97	Dec98	Dec99	Dec00	Dec01
EV-to-EBIT		Get a 7-Day Free Trial					13.61	15.87	19.21	-1.84	0.13

Response Oncology Quarterly Data
	Jun97	Sep97	Dec97	Mar98	Jun98	Sep98	Dec98	Mar99	Jun99	Sep99	Dec99	Mar00	Jun00	Sep00	Dec00	Mar01	Jun01	Sep01	Dec01	Mar02
EV-to-EBIT	Get a 7-Day Free Trial															-	-	-	-	-

For the Medical Care Facilities subindustry, Response Oncology's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

For the Healthcare Providers & Services industry and Healthcare sector, Response Oncology's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Response Oncology's EV-to-EBIT falls into.

Response Oncology EV-to-EBIT Calculation

Response Oncology's EV-to-EBIT for today is calculated as:

Response Oncology's current Enterprise Value is $0.0 Mil.
Response Oncology's EBIT for the trailing twelve months (TTM) ended in Mar. 2002 adds up the quarterly data reported by the company within the most recent 12 months, which was $-51.1 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Response Oncology  (GREY:ROIX) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

Response Oncology's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2002 is calculated as:

Response Oncology's Enterprise Value for the quarter that ended in Mar. 2002 was $-8.2 Mil.
Response Oncology's EBIT for the trailing twelve months (TTM) ended in Mar. 2002 adds up the quarterly data reported by the company within the most recent 12 months, which was $-51.1 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Response Oncology EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of Response Oncology's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

Response Oncology (Response Oncology) Business Description